ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Chinese pursuit of Avigan patent faces pushback in Japan

Fujifilm intellectual property cited as reason to 'reject' Beijing lab's application

The patent filing by China's Academy of Military Medical Sciences covers favipiravir, the generic name for Avigan, as a treatment for COVID-19.

TOKYO -- A Chinese lab attempting to patent the use of anti-flu drug Avigan for the treatment of COVID-19 is facing pushback in Japan, where the medicine was originally developed.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more